The board of directors of Sino Biopharmaceutical Limited announced that the Group has obtained a drug registration certificate from the National Medical Products Administration of China for another product of "Tofacitib Citrate Tablet" (Product specification: 5mg; Certificate no.: 2021S00528). The product was filed as a Chemicals Category 4 drug and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs. Tofacitib Citrate is a new oral protein tyrosine kinase inhibitor indicated for adult patients with moderate to severe active rheumatoid arthritis who are inadequately treated by or intolerant of methotrexate.

The approval of this product will provide an alternative drug option for rheumatoid arthritis patients in China.